search
Back to results

Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease

Primary Purpose

Gastroesophageal Reflux Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Stretta® System
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroesophageal Reflux Disease focused on measuring Gastroesophageal reflux. PPI. Radiofrequency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient above 18 years old Suffering from typical symptoms of reflux (heartburn and/or acid regurgitation and/or epigastric burns with ascending radiations) Symptoms occurring at least 3 times a week without treatment Symptoms disappearing under full doses PPI treatment Requiring a continuous treatment for more than 3 months to get rid of symptoms (or nearly) Total consent signed from patient Exclusion Criteria: Contraindications to the radiofrequency technique: Columnar lined oesophagus ³ 3 cm height Barret's mucosa presenting dysplasia History of treated columnar lined oesophagus Hiatus hernia with a size over 3 cm History of Stage C or D esophagitis in the Los Angeles classification (18), or in progress History of oesophageal stenosis History of gastric or oesophageal surgery Presence of oesophageal and/or cardial varicose veins Presence of a cardiac pacemaker or implanted defibrillator (when confirmed by the manufacturer that use of RF energy will not interfere, it's ok to do patients!) Impossibility to interrupt a anticoagulant treatment or serious disorders of haemostasis General contraindications: Contraindication to general anaesthesia Existence of an associated serious disease making fear that the patient will live less than a year Incapacity to understand and sign a sensible consent of participation to the study Chronic alcoholism defined by a daily consumption of alcohol over 60 g Morbid obesity defined by a rate of body mass higher that 35 Patients suffering from atypical GERD symptoms (especially extra-digestive) will not be included in the study if these symptoms are not associated with typical reflux symptoms (heartburn or regurgitation)

Sites / Locations

  • Nantes University Hospital

Outcomes

Primary Outcome Measures

The main endpoint will be the possibility or not to stop the PPI treatment (or to reduce the dose by at least 50%), 6 months after administering (or not) just one radiofrequency session.

Secondary Outcome Measures

The evaluation of tolerance,
the description of potential complications entailed by the technique and the measure of GERD recurrence rate on patients over a one-year period.

Full Information

First Posted
September 12, 2005
Last Updated
May 20, 2008
Sponsor
Nantes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00200642
Brief Title
Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease
Official Title
Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2008
Overall Recruitment Status
Completed
Study Start Date
December 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Nantes University Hospital

4. Oversight

5. Study Description

Brief Summary
Gastroesophageal reflux disease is a frequent disease and which heavily affects the patients' quality of life. To alleviate symptoms and ease the healing of lesion, patients very often need to continuously take anti-secretory drugs (Proton pump inhibitors or PPIs), which, despite their efficiency, do not cure the disease. For these PPI dependent patients, an anti-reflux surgery (fundoplication often made by coelioscopy) is a possible alternative but it has a significant morbidity rate and even an estimated post-operative mortality of 0.8% outside of expertise centres. Therefore, new therapeutic endoscopic approaches, supposed to be less invasive and less expensive than surgery have been developed during the last three years. Among them, radiofrequency (Stretta® procedure) consists in administering a high frequency current in the cardia area, in order to induce thanks to a thermal effect a sub-mucous remodelling and a modification of the compliance of the cardia regionThe aim of this project carried out in 8 French centres and 2 European centers is to assess through a randomised trial, the efficiency of radiofrequency on PPI dependent patients. The study will be carried out in 2 phases with patients who have been fully informed of the project statement, and particularly of the potential risks of the radiofrequency technique and have given their written acceptation to participate to the study.The first phase, which will last 6 to 11 weeks, will aim at making sure that patients are PPI dependent and define their needs. After this initial phase, patients will be randomised between those who will carry on with the PPI treatment or the radiofrequency treatment. The follow up after this randomisation will last one year. The first assessment of the therapeutic efficiency will be done at 6th month. The 6 additional follow up months will be required for the assessment of mid-term side effects of the treatment and the rate of symptomatic recurrences.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease
Keywords
Gastroesophageal reflux. PPI. Radiofrequency

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Stretta® System
Primary Outcome Measure Information:
Title
The main endpoint will be the possibility or not to stop the PPI treatment (or to reduce the dose by at least 50%), 6 months after administering (or not) just one radiofrequency session.
Secondary Outcome Measure Information:
Title
The evaluation of tolerance,
Title
the description of potential complications entailed by the technique and the measure of GERD recurrence rate on patients over a one-year period.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient above 18 years old Suffering from typical symptoms of reflux (heartburn and/or acid regurgitation and/or epigastric burns with ascending radiations) Symptoms occurring at least 3 times a week without treatment Symptoms disappearing under full doses PPI treatment Requiring a continuous treatment for more than 3 months to get rid of symptoms (or nearly) Total consent signed from patient Exclusion Criteria: Contraindications to the radiofrequency technique: Columnar lined oesophagus ³ 3 cm height Barret's mucosa presenting dysplasia History of treated columnar lined oesophagus Hiatus hernia with a size over 3 cm History of Stage C or D esophagitis in the Los Angeles classification (18), or in progress History of oesophageal stenosis History of gastric or oesophageal surgery Presence of oesophageal and/or cardial varicose veins Presence of a cardiac pacemaker or implanted defibrillator (when confirmed by the manufacturer that use of RF energy will not interfere, it's ok to do patients!) Impossibility to interrupt a anticoagulant treatment or serious disorders of haemostasis General contraindications: Contraindication to general anaesthesia Existence of an associated serious disease making fear that the patient will live less than a year Incapacity to understand and sign a sensible consent of participation to the study Chronic alcoholism defined by a daily consumption of alcohol over 60 g Morbid obesity defined by a rate of body mass higher that 35 Patients suffering from atypical GERD symptoms (especially extra-digestive) will not be included in the study if these symptoms are not associated with typical reflux symptoms (heartburn or regurgitation)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean Paul Galmiche, MD
Organizational Affiliation
Nantes UH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nantes University Hospital
City
Nantes
ZIP/Postal Code
44093
Country
France

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease

We'll reach out to this number within 24 hrs